Compare AMS & EDSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMS | EDSA |
|---|---|---|
| Founded | 1980 | 2015 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.2M | 12.3M |
| IPO Year | N/A | N/A |
| Metric | AMS | EDSA |
|---|---|---|
| Price | $2.21 | $1.03 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $13.00 |
| AVG Volume (30 Days) | 9.4K | ★ 112.9K |
| Earning Date | 11-13-2025 | 02-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $29,423,000.00 | N/A |
| Revenue This Year | $3.81 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 17.84 | N/A |
| 52 Week Low | $2.01 | $0.94 |
| 52 Week High | $3.11 | $4.49 |
| Indicator | AMS | EDSA |
|---|---|---|
| Relative Strength Index (RSI) | 63.85 | 27.97 |
| Support Level | $2.09 | $0.94 |
| Resistance Level | $2.15 | $1.11 |
| Average True Range (ATR) | 0.07 | 0.14 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 61.28 | 15.69 |
American Shared Hospital Services provides stereotactic radiosurgery equipment, Advanced radiation therapy, and related equipment. It currently provides Gamma Knife units to medical centers and stand-alone facilities. The company, along with its subsidiaries, operates through the following operations: Gamma Knife, Advanced Radiation Therapy Equipment and Services, and Proton Beam Radiation Therapy Operations. It generates most of its revenue from the domestic market.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.